---
document_datetime: 2025-11-19 11:51:20
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/exforge-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: exforge-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.9003008
conversion_datetime: 2025-12-24 02:14:24.468882
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Exforge

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific information after authorisation (archive).

| Applicationnumber   | Scope                               | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|---------------------|-------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| VariationtypeIA/    | A.5Changeinthenameand/oraddressof a | 19/11/2025                          |                                          | Annex II and                    |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedforallotherprocedures.

3SmPC(Summary ofProductCharacteristics),AnnexII,Labelling,PL(PackageLeaflet).

2 A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g.summary of product characteristics, annexII, labelling,package leaflet).The CDisissuedwithintwomonths of the opinionforvariationsfallingunderthescope ofArticle23.1a(a)ofRegulation(EU)No.712/2012,orwithinoneyearforotherprocedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000309769   | manufacturer/importer of the finished   | PL   |
|---------------------|-----------------------------------------|------|

<div style=\"page-break-after: always\"></div>

|                                          | certificate from an already approved manufacturer-Accepted B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.1I1.1.a.2 Updated certificate from an already approved manufacturer-Accepted B.III.1.aEuropeanPharmacopoeial CertificateofSuitability totherelevantPh. Eur.Monograph-B.III.1.a.2 Updated certificate from an already approved manufacturer-Accepted   |            |             |
|------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|
| Variation type IA_IN / EMA/VR/0000246587 | C.IHUMANANDVETERINARYMEDICINAL PRODUCTS - C.I.z Change(s) in the Summary of product Characteristics, LabellingorPackageLeafletintended to implementtheoutcomeofaPRACsignal recommendation: implementation of wording agreed by the competent authority that do not require any further assessment - Accepted                                                                                                         | 11/02/2025 | SmPC and PL |